Initiation, retention, and discontinuation of extended-release buprenorphine (BUP-XR) for opioid dependence
A single-arm multi-site trial in Ukraine
Datos Bibliográficos
| ID | 14909256 |
|---|---|
| Autores | Sofiia Ohorodnik (0000-0002-7179-2522, Ministry of Health, autor de correspondencia), Kyle Conroy (0009-0002-1045-9117, Chicago Department of Public Health), Kostyantyn Dumchev (0000-0003-2862-4977, Ukrainian Institute of Public Health Policy), Andrii Ptashchenko (0009-0004-5014-0332, Ministry of Health), Valeriia Gritsenko (0009-0002-6046-7318, Ministry of Health), Iryna Ivanchuk (0009-0001-9969-8650, Ukrainian Institute of Public Health Policy), Olga Morozova (0000-0001-7064-2939, Chicago Department of Public Health) |
| Año | 2026 |
| Volumen | 148 |
| Páginas | 105107 |
| Fecha de publicación | 2026-02-01 |
| Peer Reviewed | Sí |
| Open Access | Sí |
| Tipo | ARTICLE |
| Revista | International Journal of Drug Policy (JOURNAL) |
| Identificadores de la revista | ISSN: 0955-3959 • E-ISSN: 1873-4758 |
| Editorial | Elsevier BV (PUBLISHER) |
| DOI | 10.1016/j.drugpo.2025.105107 |
| PMID | 41483733 |
| OpenAlex | W7118093879 |
| Idioma | EN |
| Referencias citadas | 58 |
Buprenorphine · Clinical trial · Discontinuation · Dosing · Medical prescription · Narcotic antagonists · Opioid · Opioid-Related Disorders · HIV, Drug Use, Sexual Risk · Opioid Use Disorder Treatment · Substance Abuse Treatment and Outcomes
A Brief Measure for Assessing Generalized Anxiety Disorder
The PHQ-9
Long-Acting Injectable Buprenorphine for Opioid Use Disorder
Making long‐acting treatment work
Treatment satisfaction and patient reported outcomes among people with opioid use disorder participating in an open‐label, non‐randomised trial of long‐acting injectable buprenorphine treatment in Australian custodial settings
Mental health symptoms and coping strategies among Ukrainians during the Russia-Ukraine war in March 2022
Retention in medication-assisted treatment programs in Ukraine—Identifying factors contributing to a continuing HIV epidemic
Conceptualising retention in treatment with long-acting injectable buprenorphine (for opioid use disorder) as a journey
Retention and dropout from sublingual and extended-release buprenorphine treatment
Matters-of-concern’ associated with discontinuation of long-acting injectable buprenorphine
Treatment of opioid use disorder in Ukraine during the first year of the Russia–Ukraine war
Week Retention in Treatment With Extended-Release Subcutaneous Buprenorphine Depot Injections Among People With Opioid Dependence
I just thought that was the best thing for me to do at this point’
Tinkering with care
Development of the Alcohol Use Disorders Identification Test (Audit)
| Velocidad de citación | historical |
|---|---|
| Altamente citado | No |